271980.KS
Jeil Pharmaceutical Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 10,780.00
−1.01%Year over year
Reported trailing growth
- Revenue
- -17.9%
- EBITDA
- -65.5%
- EBIT
- -65.8%
- EPS
- +242.9%
- Free cash flow
- +73.3%
- Operating cash flow
- +149.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.8%
- EBITDA
- +35.7%
- EBIT
- +52.6%
- Net income
- +116.2%
- EPS
- +116.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026